Cardio Diagnostics Holdings Inc. Common stock
$2.00
$0.00 (+0.00%)
$1.92Day Range$2.06
Key Statistics
Market Cap
$5.92M
Shares Outstanding
3.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 26, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$1.99
Day High
$2.06
Day Low
$1.92
Volume
33.0K
VWAP
$2.00
Prev Close
$2.00
Transactions
--
Acc. Volume
--
About Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESSIC 283517 employees311 W. SUPERIOR STREET, CHICAGO, IL, 60645855-226-9991IPO Oct 26, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001870144
- Composite FIGI
- BBG013P0VV65
- Share Class FIGI
- BBG013P0VV74
- Ticker Root
- CDIO
- SIC Code
- 2835
About Cardio Diagnostics Holdings Inc. Common stock (CDIO) Stock
Cardio Diagnostics Holdings Inc. Common stock (CDIO) closed the 2026-09-16 session at $2.00, up 0.00% versus the previous close (+0.00). The stock opened at $1.99 and traded between $1.92 and $2.06 during that session. Session trading volume was 33K shares. The volume-weighted average price (VWAP) is $2.00.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Cardio Diagnostics Holdings Inc. Common stock has a market capitalization of $5.9 million. The company operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry classification. CDIO is listed on the XNAS exchange. The company employs approximately 17 people. Cardio Diagnostics Holdings Inc. Common stock is headquartered in CHICAGO, IL. The recorded listing date is 2022-10-26.
On this page you can find market CDIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.